Kleiner-Perkins, Highland Capital Fund Company Focused on iPS Technology
SAN FRANCISCO, June 16 /PRNewswire/ -- iZumi Bio, Inc., and The J. David Gladstone Institutes, an independent non-profit biomedical research organization, have announced a major research collaboration and licensing agreement to focus on applications for induced pluripotent stem (iPS) cells.
iPS cells are "reprogrammed" adult cells that have similar properties and potential to those of human embryonic stem (ES) cells, yet do not raise the same ethical concerns and can be generated in a patient-specific manner to avoid immune rejection.
"The Gladstone relationship with iZumi Bio combines our work in cardiovascular disease and stem cell science with first-class investors and an experienced management team," said Deepak Srivastava, MD, Director of the Gladstone Institute of Cardiovascular Disease (GICD). "It's an ideal model for advancing science in a focused, efficient way."
"Gladstone is emerging as a global leader in regenerative medicine and its applications to heart disease," said Thane Kreiner, PhD, iZumi Bio Chief Executive Officer. "This collaboration underscores our commitment and ability to translate the best research in iPS technology to products that address important unmet medical needs."
Elements of the broad partnership include iZumi Bio taking a license to certain Gladstone patents and sponsoring research related to iPS cells and cardiovascular disease. Dr. Srivastava will lead the research and will join iZumi Bio's scientific advisory board.
"We're delighted to add this important new company to our translational research partners," said Gladstone President, Robert W. Mahley, MD, PhD. "We look forward to developing iPS technology into treatments and cures."
About the Gladstone
|SOURCE iZumi Bio, Inc.|
Copyright©2008 PR Newswire.
All rights reserved